60 Degrees Pharmaceuticals Proposes Second Reverse Stock Split (1:5 to 1:10) and Massive Equity Plan Increase Amid Going Concern

summarizeSummary

60 Degrees Pharmaceuticals is proposing a second reverse stock split (1:5 to 1:10) and a highly dilutive 800,000 share increase to its equity plan, alongside a management success fee for a potential sale, all against a backdrop of severe financial distress and going concern warnings.

check_boxKey Events

• Proposed Second Reverse Stock Split (1:5 to 1:10)

  Shareholders will vote on a proposal to effect a reverse stock split at a ratio between 1:5 and 1:10, at the Board's discretion. This follows a 1:4 reverse split on January 20, 2026, and is primarily aimed at maintaining the company's Nasdaq listing due to low share price. This indicates ongoing and severe challenges in meeting listing requirements.

• Massive Increase to Equity Incentive Plan Shares

  The company proposes to increase the shares available for issuance under its 2022 Equity Incentive Plan by 800,000 shares. If a 1:10 reverse split is implemented, these 962,889 total shares for the plan would represent approximately 362% of the new outstanding shares, indicating extreme potential dilution for existing shareholders through employee compensation.

• Management Success Fee for Strategic Transactions

  Shareholders will vote on approving a management success fee of 5% to 6% of deal proceeds for a change of control, strategic transaction, or sale of the Arakoda drug. This incentivizes management to pursue a sale, which could be a necessary step given the company's 'going concern' status and critical cash runway.

• New Director Nominee with M&A Experience

  Eric Francois, a financial executive with experience in capital raising and M&A, is nominated to the Board, replacing Charles Allen. This appointment aligns with the company's stated need for strategic transactions and capital solutions.

auto_awesomeAnalysis

This preliminary proxy statement reveals critical proposals for the upcoming annual meeting, highlighting the company's severe financial distress. The most impactful proposal is a potential second reverse stock split, ranging from 1:5 to 1:10, just five months after a 1:4 reverse split in January 2026. This indicates persistent challenges in maintaining Nasdaq listing requirements and a desperate need to boost share price. Concurrently, the company seeks to authorize an additional 800,000 shares for its equity incentive plan, which, if a 1:10 reverse split occurs, would represent an astronomical 362% of the new outstanding shares, signaling extreme potential dilution for existing shareholders. Furthermore, a proposal for a management success fee (5-6% of deal value) for a change of control or strategic transaction, while potentially incentivizing a sale, underscores the company's precarious position and the urgency for a significant corporate event. These actions collectively point to a company struggling for survival, with a high risk of further shareholder value erosion.